v3.26.3
Significant Contracts - Additional Information (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 19, 2025
USD ($)
$ / shares
shares
May 31, 2024
USD ($)
Dec. 31, 2026
USD ($)
Sep. 30, 2026
USD ($)
shares
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
shares
Sep. 30, 2025
USD ($)
Dec. 31, 2023
USD ($)
Sep. 30, 2026
SFr / shares
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2025
SFr / shares
May 19, 2025
SFr / shares
Jun. 08, 2023
SFr / shares
Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue       $ 12,669,000 $ 889,000 $ 24,308,000 $ 2,646,000              
Current deferred revenue       2,546,000   2,546,000       $ 15,771,000        
Collaboration Expense       $ 41,284,000 57,115,000 $ 127,505,000 159,777,000              
Common stock, shares issued | shares       96,930,842   96,930,842       96,009,657        
Common shares, nominal value | SFr / shares                 SFr 0.03   SFr 0.03   SFr 0.03  
Research and development       $ 71,888,000 58,902,000 $ 207,614,000 201,280,000              
A&R Vertex JDCA [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Percentage of net profits and net losses                           40.00%
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue       0 0 0 0              
Collaboration Expense       41,300,000 57,100,000 127,500,000 159,800,000              
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Milestone payment receivable       410,000,000   410,000,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | A&R Vertex JDCA [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Percentage of net profits and net losses                           60.00%
Current payment due               $ 20,000,000            
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Non-Ex License Agreement [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Milestone payment receivable       125,000,000   125,000,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2019 Collaborative Agreement [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum potential future payments           775,000,000                
Vertex Pharmaceuticals Inc [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Proceeds from letter agreement   $ 43,000,000                        
Net proceeds from transfer   42.00%                        
Reimbursements from research and license agreements       4,000,000 $ 400,000 8,200,000 $ 1,100,000              
Vertex Pharmaceuticals Inc [Member] | 2019 Collaborative Agreement [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue       12,300,000   12,300,000                
Current deferred revenue       12,300,000   12,300,000                
Sirius Therapeutics [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Reimbursements from research and license agreements       600,000   $ 1,300,000                
Upfront cash payment $ 25,000,000                          
Common stock, shares issued | shares 70,000,000                          
Issuance of common shares | shares 1,842,105         1,842,105                
Common shares, nominal value | SFr / shares                       SFr 0.03    
Share issued price | $ / shares $ 38                          
Remaining milestone payable       12,500,000                    
One time payment per option $ 10,000,000                          
Future development regulatory and sales milestone payment 300,000,000                          
Research and development       5,400,000   $ 10,400,000                
Sirius Therapeutics [Member] | Forecast [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Cash payments on development milestone     $ 12,500,000                      
Sirius Therapeutics [Member] | Maximum [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Milestones aggregate payment $ 87,500,000         75,000,000                
Remaining milestone payment receivable       $ 75,000,000   75,000,000                
Future development regulatory and sales milestone payment           $ 300,000,000